From Coverage to Cure: a data-driven roadmap to accelerate Universal Health Insurance and secure patients' access to medicines in Egypt

Egypt's Universal Health Insurance (UHI) system, established by Law No. 2 of 2018, is the state's flagship instrument for delivering Egypt Vision 2030's commitment to accessible, quality healthcare for every citizen. Phase one is complete in six governorates, and phase two — led by Minya and covering more than 12 million people — is now under way. In October 2026 a Prime Ministerial committee set the direction clearly: plan for completion within no more than ten years and cover 50% of the population by 2030. Accelerating coverage at this pace is not only a question of hospitals and enrolment; it is a question of medicines. Every new beneficiary becomes a prescription that must be forecast, procured, priced, manufactured and dispensed. Egypt has strong foundations: a WHO Maturity Level 3 regulator, local production that meets about 91% of medicine needs, a single public bulk purchaser, and more than 81 million electronic prescriptions inside UHI itself. This policy brief argues that the speed of UHI will increasingly be set by the medicines value chain. It proposes five practical, low-cost measures: a national UHI Medicines Intelligence Platform that links existing data into one forecasting layer; a standard Medicine Readiness Study before each governorate enters the system; multi-year, volume-based "local-first" framework agreements to support manufacturing and API localisation; an institutionalised health technology assessment and managed-entry pathway for high-cost medicines; and a last-mile pharmacy access network, starting in Minya. The recommendations require coordination more than new spending, and each can be piloted within the current legal framework. An Arabic version of the full paper is included as an additional file.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-15
DOI
https://doi.org/10.5281/zenodo.24245770
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Coverage to Cure: a data-driven roadmap to accelerate Universal Health Insurance and secure patients' access to medicines in Egypt

Mohammad Osama Alsaadany
Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Economics and Policy
article

From Coverage to Cure: a data-driven roadmap to accelerate Universal Health Insurance and secure patients' access to medicines in Egypt

Mohammad Osama Alsaadany
article en

Abstract

Egypt's Universal Health Insurance (UHI) system, established by Law No. 2 of 2018, is the state's flagship instrument for delivering Egypt Vision 2030's commitment to accessible, quality healthcare for every citizen. Phase one is complete in six governorates, and phase two — led by Minya and covering more than 12 million people — is now under way. In October 2026 a Prime Ministerial committee set the direction clearly: plan for completion within no more than ten years and cover 50% of the population by 2030. Accelerating coverage at this pace is not only a question of hospitals and enrolment; it is a question of medicines. Every new beneficiary becomes a prescription that must be forecast, procured, priced, manufactured and dispensed. Egypt has strong foundations: a WHO Maturity Level 3 regulator, local production that meets about 91% of medicine needs, a single public bulk purchaser, and more than 81 million electronic prescriptions inside UHI itself. This policy brief argues that the speed of UHI will increasingly be set by the medicines value chain. It proposes five practical, low-cost measures: a national UHI Medicines Intelligence Platform that links existing data into one forecasting layer; a standard Medicine Readiness Study before each governorate enters the system; multi-year, volume-based "local-first" framework agreements to support manufacturing and API localisation; an institutionalised health technology assessment and managed-entry pathway for high-cost medicines; and a last-mile pharmacy access network, starting in Minya. The recommendations require coordination more than new spending, and each can be piloted within the current legal framework. An Arabic version of the full paper is included as an additional file.

Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon